7 results about "Cyclin D1" patented technology

Disclosed herein are methods for increasing sensitivity of a cancer cell to alternating electric fields by administering an AKT inhibitor, a mammalian target of rapamycin (mTOR) inhibitor, a Phosphatidylinositol 3-Kinase (PI3K) inhibitor, and / or a Glycogen synthase kinase 3β (GSK3β) inhibitor. Disclosed are methods of increasing treatment efficacy comprising applying alternating electric fields to a target site of the subject for a period of time, the alternating electric fields having a frequency and field strength, wherein the target site comprises one or more cancer cells, and administering a therapeutically effective amount of one or more of an mTOR inhibitor, AKT inhibitor, PI3K inhibitor, or GSK3β inhibitor to the subject. Disclosed are methods of reducing viability of cancer cells using alternating electric fields for a period of time, the alternating electric fields having a frequency and field strength in combination with either an mTOR inhibitor, AKT inhibitor, PI3K inhibitor, or GSK3β inhibitor and / or a composition or compound that increases cyclin D1. Disclosed are methods of increasing apoptosis of a cancer cell comprising exposing the cancer cell to alternating electric fields for a period of time, the alternating electric fields having a frequency and field strength; and exposing the cancer cell to a PI3K inhibitor.

The invention belongs to the technical field of biological medicine, and particularly relates to application of a Gli activator in preparation of a product for treating fiberosity. The invention provides an application of a Gli activator in preparation of a product for preventing and / or treating fiber hair disease. The Gli activator comprises an overexpressed Gli adenovirus, an overexpressed Gli adeno-associated virus, a nucleic acid molecule for improving Gli expression and a small molecule compound for activating Gli. The application accidentally finds that the Gli2 adenovirus can remarkably correct the skeleton phenotype of a mouse model of JATD caused by IFT88 deletion, and the activator with the Gli transcription factor as the target spot can promote the expression of a proliferation related gene c-MYC, or n-MYC, or Cyclin D1; the expression of the apoptosis related gene Bcl2 is inhibited; therefore, bone and cartilage cell proliferation is promoted; bone and cartilage cell apoptosis is reduced; and the effect of activating bone and cartilage cells is achieved, so that the fibrinosis is prevented and / or treated, and a potential target and a new treatment scheme are provided for clinical treatment of generalized fibrinosis.

The application discloses a plant lactobacillus plantarum CCFM1351 prepared metaplasma based on multi-target for preventing hair loss and protecting hair, and belongs to the technical field of microorganisms and the technical field of medicine. The plant lactobacillus plantarum CCFM1351 prepared metaplasma has the functions of regulating hair follicle development and inhibiting apoptosis, can inhibit the expression of BAX, TGF-beta 2 and DKK-1 of hair follicle dermal papilla cells (HDPC), and promote the expression of VEGF in HDPC. Compared with the same concentration of Platycladus orientalis, the Platycladus orientalis fermentation supernatant prepared by the plant lactobacillus plantarum CCFM1351 can promote the expression of Cyclin D1 mRNA and IGF-1 mRNA of HDPC. The plant lactobacillus plantarum CCFM1351 prepared metaplasma can be used for preparing products for preventing and / or treating hair loss, and has great application prospect.

The invention discloses application of aloperine to regulation of expression levels of GSPT1, Caspase-3, Caspase-9, Bax and Bcl-2 and an evaluation method of aloperine, and relates to the technical field of biological medicines.The method comprises the following steps that aloperine with different concentrations is used for treating gastric cancer HGC-27 cells and AGS cells, and proliferation activity is evaluated through a cytotoxicity experiment, a cell proliferation experiment and a plate cloning experiment; according to the method, migration and repair capability is evaluated by applying a scratch experiment, migration and invasion capability is detected by applying an invasion experiment, cell cycle change conditions are analyzed by using flow cytometry, mRNA expression levels of GSPT1, CDK4, Cyclin D1, Caspase-3, Caspase-9, Bax and Bcl-2 are determined by applying a real-time fluorescent quantitative polymerase chain reaction experiment, and protein expression levels of GSPT1, Caspase-3, Caspase-9, Bax and Bcl-2 are evaluated by applying a western blot experiment. The invention provides the application of aloperine in regulating the expression levels of GSPT1, Caspase-3, Caspase-9, Bax and Bcl-2, and a brand new path is provided for precise diagnosis and treatment of gastric cancer.

Compositions and methods for treating or preventing cancer comprising at least one compound of general Formula (I), preferably compounds of general Formula IIA (IIA).

A method for treating retinal degenerative diseases in a subject, which involves administering an agonist to selectively elevate cyclin D1 expression in Müller glia (MG) cells, and administering an antagonist to selectively knock down p27Kip1 expression in MG cells.

This invention discloses the application of UFSP2 as a target in the preparation of prostate cancer therapeutic products. This invention relates to the biomedical field, and research has found that UFM1-specific protease 2 (UFSP2) is highly expressed in prostate cancer tissues, with protein levels higher than in adjacent normal tissues, and is positively correlated with the expression of proliferation-related molecules c-Myc and Cyclin D1. Functional experiments further show that inhibiting UFSP2 expression significantly inhibits the proliferation, colony formation, and migration of prostate cancer cells, and inhibits in vivo tumor growth and metastasis; conversely, overexpression of UFSP2 promotes prostate cancer cell proliferation, indicating that UFSP2 can serve as a therapeutic target for prostate cancer and can be used to screen anti-prostate cancer drugs. This invention provides the application of UFSP2 expression inhibitors and / or functional inhibitors in the preparation of prostate cancer therapeutic products, offering a new direction for drug development and targeted intervention strategies for prostate cancer treatment.